Checkpoint inhibitors such as CTLA4 and PD1/PDL1 serve to relieve suppression of existing tumor-specific T cells, and these antibodies and other costimulatory antibodies also have the potential to generate new anti-tumor immune responses by supporting expansion of new tumor-specific T cells that were previously not involved in tumor control9–12. This evidence concerns the gene CTLA4 and neoplasm.